Nurix Therapeutics: Sanofi to end SAR448272 trial

Nurix does not expect future SAR448272 milestones or royalties; other licensed programs remain eligible if Sanofi chooses to develop them further.

Available on EDGAR 11/03/2026 - 04:02 PM EST Accepted by SEC EDGAR 11/03/2026 - 04:02 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. (NRIX) said collaboration partner Sanofi S.A. notified it of a decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and terminate the program. Nurix does not expect future development, regulatory or commercial milestone payments or royalties under the Sanofi collaboration with respect to SAR448272. Nurix remains eligible for milestone payments and royalties on other previously announced licensed programs that Sanofi may, at its discretion, develop further into clinical candidates. The company cited the risk that Sanofi may not advance those programs and that collaborators may discontinue or delay partnered-program development.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Clinical trial phase: Phase 1

1 metrics

Clinical trial phase Phase 1 SAR448272 first-in-human clinical trial

Key Terms

first-in-human clinical trial, STAT6 degrader, milestone payments

3 terms

first-in-human clinical trial medical

"the Phase 1 first-in-human clinical trial of SAR448272"

A first-in-human clinical trial is the first time a new drug or medical treatment is given to people rather than tested only in the lab or animals, aimed mainly at checking safety, appropriate dose, and initial side effects. For investors, it marks a major step from concept to real-world testing—like taking a prototype car onto a closed track—and carries high risk but also the potential to unlock significant value if results are favorable.

STAT6 degrader medical

"SAR448272, an oral STAT6 degrader"

A STAT6 degrader is a drug designed to remove the STAT6 protein inside cells by tagging it for disposal, rather than merely blocking its activity. STAT6 is a cellular switch that controls genes involved in immune responses and inflammation, so degrading it can shut down those signals; for investors, this class of therapy matters because it represents a specific mode of action that can create new treatment opportunities and affect clinical and commercial value for biotech firms developing such molecules.

milestone payments financial

"development, regulatory or commercial milestone payments"

Milestone payments are predetermined sums a company agrees to pay or receive when specific development, regulatory, or commercial goals are reached in a partnership or license deal. Think of them like progress bonuses: they turn uncertain future outcomes into conditional cash events, so investors track them as potential sources of revenue, value inflection points, and risk—payments only arrive if the agreed milestones are actually achieved.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What happened to NRIX’s SAR448272 trial?

Sanofi notified Nurix that it decided to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and terminate the program.

Can NRIX still receive milestone payments from Sanofi?

Nurix remains eligible for milestone payments and royalties from other previously announced licensed programs under the Sanofi collaboration, if Sanofi chooses to develop those programs further into clinical candidates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001549595false11/3/20261600 Sierra Point ParkwayBrisbaneCalifornia00015495952026-11-032026-11-03

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 3, 2026

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________

Delaware			001-39398			27-0838048
(State or Other Jurisdiction of Incorporation or Organization)			(Commission File Number)			(IRS Employer Identification No.)
1600 Sierra Point Parkway, Brisbane, California						94005
(Address of Principal Executive Offices)						(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code) 

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class			Trading symbol(s)			Name of each exchange on which registered
Common Stock, $0.001 par value per share			NRIX			Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01    Other Events.

On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an oral STAT6 degrader, and to terminate the SAR448272 program.

As a result of Sanofi’s decision, the Company does not expect to receive any of the future development, regulatory and commercial milestone payments or royalties for which it was eligible under the Company’s collaboration with Sanofi (the “Sanofi Collaboration”) with respect to the SAR448272 program. The Company remains eligible to receive milestone payments and royalties with respect to its other previously announced licensed programs developed under the Sanofi Collaboration that Sanofi may at its discretion develop further into clinical candidates.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Those risks include the risk that Sanofi may choose not to advance other licensed programs under the Sanofi Collaboration, the risk that the Company’s collaborators may discontinue or delay the development of partnered programs, and the other risks described under the heading “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended August 31, 2026, and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this report, and the Company undertakes no obligation to update them, except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NURIX THERAPEUTICS, INC.
Date: November 3, 2026			By:			/s/ Christine Ring
						Christine Ring, Ph.D., J.D.
						Chief Legal Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB